For example, SGLT2i and GLP-1 RAs are already available glucose-lowering agents that promote modest reductions in weight and are likely to play a greater role in the management of diabetes in the future, especially given the favourable results of their use in recent cardiovascular outcome trials. This evidence concerns the gene GLP1R and diabetes mellitus.